Balakumar Swaminathan
Mount Sinai Hospital
ON, Canada
ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Published: February 01, 2024
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Journal: Ophthalmology
Published: August 09, 2023
A hybrid automated event adjudication system for clinical trials.
Journal: Clinical trials (London, England)
Published: February 03, 2023
Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Published: January 11, 2023
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Journal: Lancet (London, England)
Published: August 31, 2021
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
Journal: Ophthalmology science
Published: June 11, 2021
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Journal: JAMA neurology
Published: April 09, 2019
Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials.
Journal: Ophthalmology
Published: March 11, 2019
The cost implication of primary prevention in the HOPE 3 trial.
Journal: European heart journal. Quality of care & clinical outcomes
Published: October 07, 2018
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Journal: The Lancet. Neurology
Published: June 30, 2018
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Journal: The New England journal of medicine
Published: May 17, 2018
Last Updated: 09/26/2026